X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Pfizer with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs TEVA PHARMA (Israel) - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PFIZER   TEVA PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-18
TEVA PHARMA
Dec-13
PFIZER/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs2,3652,979-   
Low Rs1,6252,588-   
Sales per share (Unadj.) Rs430.31,709.7-  
Earnings per share (Unadj.) Rs78.7106.8-  
Cash flow per share (Unadj.) Rs93.2245.0-  
Dividends per share (Unadj.) Rs20.0093.49-  
Dividend yield (eoy) %1.03.4 29.8%  
Book value per share (Unadj.) Rs586.51,899.1-  
Shares outstanding (eoy) m45.75848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.61.6 284.8%   
Avg P/E ratio x25.326.1 97.3%  
P/CF ratio (eoy) x21.411.4 188.4%  
Price / Book Value ratio x3.41.5 232.1%  
Dividend payout %25.487.5 29.0%   
Avg Mkt Cap Rs m91,2712,360,349 3.9%   
No. of employees `0002.644.9 5.9%   
Total wages/salary Rs m3,1430-   
Avg. sales/employee Rs Th7,484.832,257.4 23.2%   
Avg. wages/employee Rs Th1,195.00-   
Avg. net profit/employee Rs Th1,369.12,015.1 67.9%   
INCOME DATA
Net Sales Rs m19,6851,449,810 1.4%  
Other income Rs m1,1430-   
Total revenues Rs m20,8281,449,810 1.4%   
Gross profit Rs m5,003397,031 1.3%  
Depreciation Rs m663117,190 0.6%   
Interest Rs m428,477 0.0%   
Profit before tax Rs m5,479251,365 2.2%   
Minority Interest Rs m01,142 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-165,007 0.0%   
Tax Rs m1,878-3,069 -61.2%   
Profit after tax Rs m3,60190,569 4.0%  
Gross profit margin %25.427.4 92.8%  
Effective tax rate %34.3-1.2 -2,808.0%   
Net profit margin %18.36.2 292.8%  
BALANCE SHEET DATA
Current assets Rs m24,167979,196 2.5%   
Current liabilities Rs m9,544853,942 1.1%   
Net working cap to sales %74.38.6 859.8%  
Current ratio x2.51.1 220.8%  
Inventory Days Days5591 60.7%  
Debtors Days Days2996 29.9%  
Net fixed assets Rs m9,514473,540 2.0%   
Share capital Rs m4583,569 12.8%   
"Free" reserves Rs m26,3750-   
Net worth Rs m26,8321,610,464 1.7%   
Long term debt Rs m25741,320 0.0%   
Total assets Rs m36,9003,313,281 1.1%  
Interest coverage x1,305.59.8 13,285.2%   
Debt to equity ratio x00.5 0.2%  
Sales to assets ratio x0.50.4 121.9%   
Return on assets %9.83.6 271.9%  
Return on equity %13.45.6 238.6%  
Return on capital %20.44.9 414.0%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-1,4660-   
CASH FLOW
From Operations Rs m3,318231,025 1.4%  
From Investments Rs m-2,383-81,861 2.9%  
From Financial Activity Rs m-1,104-277,130 0.4%  
Net Cashflow Rs m-169-127,966 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 71.37 Rs / USD

Compare PFIZER With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare PFIZER With: SUN PHARMA  NOVARTIS  SANOFI INDIA  PLETHICO PHARMA  VENUS REMEDIES  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Nov 20, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS